Kayne Anderson Rudnick Investment Management
ACAD icon

Kayne Anderson Rudnick Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-55
Closed -$1K – 600
2022
Q1 		$1K Buy
+55
New +$1.33K ﹤0.01% 612
2021
Q1 		– Sell
-16
Closed -$1K – 558
2020
Q4 		$1K Buy
+16
New +$794 ﹤0.01% 562

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's ACAD Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 55 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in ACAD in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 55 Acadia Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Kayne Anderson Rudnick Investment Management's Acadia Pharmaceuticals position peaked at $1K in Q1 2022.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.